亞洲證券市場報告2015年11月26日- Regeneus Ltd (ASX:RGS)開始犬類癌症疫苗試驗
Regeneus (ASX:RGS),一家臨床階段再生醫藥公司,今天宣布開始其犬類癌症疫苗技術Kvax試驗,結合化學療法治療犬類淋巴瘤。
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.
Regeneus (ASX:RGS),一家臨床階段再生醫藥公司,今天宣布開始其犬類癌症疫苗技術Kvax試驗,結合化學療法治療犬類淋巴瘤。